|
|
|
Male |
Female |
|
|
|
|
|
Dahan 2016
|
France
|
RCT
|
T: 28
C: 24
|
T: 9
C: 14
|
T: 53.0 (42.0-63.0)
C: 58.5 (43.0-64.0)
|
T: NIAT+RTX
C: NIAT
|
23
|
T: 7680.0 (4584.3-10399.0)
C: 7195.1 (5363.1-8965.1)
|
T: 24
C: 13
|
Seitz-Polski 2017
|
France
|
RCT
|
T: 23
C: 19
|
T: 6
C: 10
|
T: 52.0 (41.0-63.0)
C: 59.0 (44.0-63.0)
|
T: RTX
C: NIAT
|
23
|
T: 7.4 (6.2-9.0)
C: 8.4 (4.4-11.0)
|
T: 19
C: 13
|
Rosenzwajg 2017
|
France
|
RCT
|
T: 16
C: 9
|
T: 16
C: 9
|
T: 57.0 (26.0-74.0)
C: 57.0 (26.0-74.0)
|
T: NIAT+RTC
C: NIAT
|
6
|
T: 7590 (3440.0-11000.0)
C: 6250 (3170.0-15900.0)
|
T: 9
C: 5
|
van den Brand 2017
|
Italy
|
Prospective cohort study
|
T: 72
C: 76
|
T: 28
C: 27
|
T: 51.5±15.9
C: 55.3±12.7
|
T: RTX
C: steroid+ cyclical CYC
|
40
|
T: 6400 (4400.0-8894.0)
C: 8840 (5651.0-11660.0)
|
T: 90
C: 123
|
Fervenza 2019
|
Canada
|
RCT
|
T: 47
C: 53
|
T: 18
C: 12
|
T: 51.9±12.6
C: 52.2±12.4
|
T: RTX
C: CYC
|
24
|
T: 8.9 (6.8-12.3)
C: 8.9 (6.7-12.9)
|
T: 39
C: 13
|
Fenoglio (SD) 2020
|
Italy
|
Retrospective case-control study
|
T: 9
C: 8
|
T: 6
C: 6
|
T: 61.4±11.5
C: 67.1±17.5
|
T: RTX
C: Ponticelli Protocol*
|
24
|
T: 5.1±1.4
C: 8.3±4.8
|
T: 13
C: 12
|